Guidelines-based treatment associated with improved economic outcomes in non-tuberculous mycobacterial lung disease

Theodore K. Marras, Mehdi Mirsaeidi, Christopher Vinnard, Edward D. Chan, Gina Eagle, Raymond Zhang, Ping Wang, Quanwu Zhang

Research output: Contribution to journalArticle

Abstract

Background: The prevalence of non-tuberculous mycobacterial lung disease (NTMLD) in the US has increased; however, data characterizing the associated healthcare utilization and expenditure at the national level are limited. Objective: To examine associations between economic outcomes and the use of anti-Mycobacterium avium complex (MAC) guidelines-based treatment (GBT) for newly-diagnosed NTMLD in a US national managed care claims database (Optum Clinformatics Data Mart). Methods: NTMLD was defined as having ≥2 claims for NTMLD (ICD-9 031.0; ICD-10 A31.0) on separate occasions ≥30 days apart (between 2007 and 2016). The cohort included patients insured continuously over a period of at least 36 months (12 months before initial NTMLD diagnostic claim and for the subsequent 24 months). Treatment was classified as GBT (consistent with American Thoracic Society/Infectious Diseases Society of America guidelines), non-GBT, or untreated. All-cause hospitalization rates and total healthcare expenditures at Year 2 were assessed as outcomes of the treatment prescribed in Year 1 after NTMLD diagnosis. Results: A total of 1,039 patients met study criteria for NTMLD (GBT, n = 294; non-GBT, n = 298; untreated, n = 447). After adjustment for baseline characteristics, GBT was associated with a significantly lower all-cause hospitalization risk vs non-GBT (odds ratio [OR] = 0.53; 95% CI = 0.33–0.85, p = 0.008), and vs being untreated (OR = 0.57; 95% CI = 0.35–0.91, p = 0.020). Adjusted total healthcare expenditure in Year 2 with GBT ($69,691) was lower than that with non-GBT ($77,624) with a difference of −$7,933 (95% CI = −$14,968 to −$899; p = 0.03). Conclusions: Patients with NTMLD in a US managed claims database who were prescribed GBT had lower hospitalization risk than those who were prescribed non-GBT or were untreated. GBT was associated with lower total healthcare expenditure compared with non-GBT.

Original languageEnglish (US)
JournalJournal of Medical Economics
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lung Diseases
Economics
Guidelines
Health Expenditures
Therapeutics
Delivery of Health Care
Hospitalization
International Classification of Diseases
Odds Ratio
Databases
Mycobacterium avium Complex
Managed Care Programs

Keywords

  • Cost
  • expenditure
  • healthcare utilization
  • hospitalization
  • non-tuberculous mycobacteria
  • pulmonary

ASJC Scopus subject areas

  • Health Policy

Cite this

Guidelines-based treatment associated with improved economic outcomes in non-tuberculous mycobacterial lung disease. / Marras, Theodore K.; Mirsaeidi, Mehdi; Vinnard, Christopher; Chan, Edward D.; Eagle, Gina; Zhang, Raymond; Wang, Ping; Zhang, Quanwu.

In: Journal of Medical Economics, 01.01.2019.

Research output: Contribution to journalArticle

Marras, Theodore K. ; Mirsaeidi, Mehdi ; Vinnard, Christopher ; Chan, Edward D. ; Eagle, Gina ; Zhang, Raymond ; Wang, Ping ; Zhang, Quanwu. / Guidelines-based treatment associated with improved economic outcomes in non-tuberculous mycobacterial lung disease. In: Journal of Medical Economics. 2019.
@article{e723fc06b4504daa9a32dd0a0069ffd3,
title = "Guidelines-based treatment associated with improved economic outcomes in non-tuberculous mycobacterial lung disease",
abstract = "Background: The prevalence of non-tuberculous mycobacterial lung disease (NTMLD) in the US has increased; however, data characterizing the associated healthcare utilization and expenditure at the national level are limited. Objective: To examine associations between economic outcomes and the use of anti-Mycobacterium avium complex (MAC) guidelines-based treatment (GBT) for newly-diagnosed NTMLD in a US national managed care claims database (Optum Clinformatics Data Mart). Methods: NTMLD was defined as having ≥2 claims for NTMLD (ICD-9 031.0; ICD-10 A31.0) on separate occasions ≥30 days apart (between 2007 and 2016). The cohort included patients insured continuously over a period of at least 36 months (12 months before initial NTMLD diagnostic claim and for the subsequent 24 months). Treatment was classified as GBT (consistent with American Thoracic Society/Infectious Diseases Society of America guidelines), non-GBT, or untreated. All-cause hospitalization rates and total healthcare expenditures at Year 2 were assessed as outcomes of the treatment prescribed in Year 1 after NTMLD diagnosis. Results: A total of 1,039 patients met study criteria for NTMLD (GBT, n = 294; non-GBT, n = 298; untreated, n = 447). After adjustment for baseline characteristics, GBT was associated with a significantly lower all-cause hospitalization risk vs non-GBT (odds ratio [OR] = 0.53; 95{\%} CI = 0.33–0.85, p = 0.008), and vs being untreated (OR = 0.57; 95{\%} CI = 0.35–0.91, p = 0.020). Adjusted total healthcare expenditure in Year 2 with GBT ($69,691) was lower than that with non-GBT ($77,624) with a difference of −$7,933 (95{\%} CI = −$14,968 to −$899; p = 0.03). Conclusions: Patients with NTMLD in a US managed claims database who were prescribed GBT had lower hospitalization risk than those who were prescribed non-GBT or were untreated. GBT was associated with lower total healthcare expenditure compared with non-GBT.",
keywords = "Cost, expenditure, healthcare utilization, hospitalization, non-tuberculous mycobacteria, pulmonary",
author = "Marras, {Theodore K.} and Mehdi Mirsaeidi and Christopher Vinnard and Chan, {Edward D.} and Gina Eagle and Raymond Zhang and Ping Wang and Quanwu Zhang",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/13696998.2019.1620243",
language = "English (US)",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Guidelines-based treatment associated with improved economic outcomes in non-tuberculous mycobacterial lung disease

AU - Marras, Theodore K.

AU - Mirsaeidi, Mehdi

AU - Vinnard, Christopher

AU - Chan, Edward D.

AU - Eagle, Gina

AU - Zhang, Raymond

AU - Wang, Ping

AU - Zhang, Quanwu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The prevalence of non-tuberculous mycobacterial lung disease (NTMLD) in the US has increased; however, data characterizing the associated healthcare utilization and expenditure at the national level are limited. Objective: To examine associations between economic outcomes and the use of anti-Mycobacterium avium complex (MAC) guidelines-based treatment (GBT) for newly-diagnosed NTMLD in a US national managed care claims database (Optum Clinformatics Data Mart). Methods: NTMLD was defined as having ≥2 claims for NTMLD (ICD-9 031.0; ICD-10 A31.0) on separate occasions ≥30 days apart (between 2007 and 2016). The cohort included patients insured continuously over a period of at least 36 months (12 months before initial NTMLD diagnostic claim and for the subsequent 24 months). Treatment was classified as GBT (consistent with American Thoracic Society/Infectious Diseases Society of America guidelines), non-GBT, or untreated. All-cause hospitalization rates and total healthcare expenditures at Year 2 were assessed as outcomes of the treatment prescribed in Year 1 after NTMLD diagnosis. Results: A total of 1,039 patients met study criteria for NTMLD (GBT, n = 294; non-GBT, n = 298; untreated, n = 447). After adjustment for baseline characteristics, GBT was associated with a significantly lower all-cause hospitalization risk vs non-GBT (odds ratio [OR] = 0.53; 95% CI = 0.33–0.85, p = 0.008), and vs being untreated (OR = 0.57; 95% CI = 0.35–0.91, p = 0.020). Adjusted total healthcare expenditure in Year 2 with GBT ($69,691) was lower than that with non-GBT ($77,624) with a difference of −$7,933 (95% CI = −$14,968 to −$899; p = 0.03). Conclusions: Patients with NTMLD in a US managed claims database who were prescribed GBT had lower hospitalization risk than those who were prescribed non-GBT or were untreated. GBT was associated with lower total healthcare expenditure compared with non-GBT.

AB - Background: The prevalence of non-tuberculous mycobacterial lung disease (NTMLD) in the US has increased; however, data characterizing the associated healthcare utilization and expenditure at the national level are limited. Objective: To examine associations between economic outcomes and the use of anti-Mycobacterium avium complex (MAC) guidelines-based treatment (GBT) for newly-diagnosed NTMLD in a US national managed care claims database (Optum Clinformatics Data Mart). Methods: NTMLD was defined as having ≥2 claims for NTMLD (ICD-9 031.0; ICD-10 A31.0) on separate occasions ≥30 days apart (between 2007 and 2016). The cohort included patients insured continuously over a period of at least 36 months (12 months before initial NTMLD diagnostic claim and for the subsequent 24 months). Treatment was classified as GBT (consistent with American Thoracic Society/Infectious Diseases Society of America guidelines), non-GBT, or untreated. All-cause hospitalization rates and total healthcare expenditures at Year 2 were assessed as outcomes of the treatment prescribed in Year 1 after NTMLD diagnosis. Results: A total of 1,039 patients met study criteria for NTMLD (GBT, n = 294; non-GBT, n = 298; untreated, n = 447). After adjustment for baseline characteristics, GBT was associated with a significantly lower all-cause hospitalization risk vs non-GBT (odds ratio [OR] = 0.53; 95% CI = 0.33–0.85, p = 0.008), and vs being untreated (OR = 0.57; 95% CI = 0.35–0.91, p = 0.020). Adjusted total healthcare expenditure in Year 2 with GBT ($69,691) was lower than that with non-GBT ($77,624) with a difference of −$7,933 (95% CI = −$14,968 to −$899; p = 0.03). Conclusions: Patients with NTMLD in a US managed claims database who were prescribed GBT had lower hospitalization risk than those who were prescribed non-GBT or were untreated. GBT was associated with lower total healthcare expenditure compared with non-GBT.

KW - Cost

KW - expenditure

KW - healthcare utilization

KW - hospitalization

KW - non-tuberculous mycobacteria

KW - pulmonary

UR - http://www.scopus.com/inward/record.url?scp=85067583050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067583050&partnerID=8YFLogxK

U2 - 10.1080/13696998.2019.1620243

DO - 10.1080/13696998.2019.1620243

M3 - Article

C2 - 31094592

AN - SCOPUS:85067583050

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

ER -